Achillion Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

Description: Achillion Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct's pharmaceuticals report, "Achillion Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011" provides data on the Achillion Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Achillion Pharmaceuticals, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Achillion Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Achillion Pharmaceuticals, Inc. - Brief Achillion Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Achillion Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Achillion Pharmaceuticals, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Achillion Pharmaceuticals, Inc. pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Achillion Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Achillion Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Achillion Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Achillion Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Achillion Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Achillion Pharmaceuticals, Inc.; Achillion Pharmaceuticals, Inc. - Key Therapeutics; Achillion Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Achillion Pharmaceuticals, Inc. - News; Achillion Pharmaceuticals, Inc. - Latest Updates; Achillion Pharmaceuticals, Inc. - Pipeline; Achillion Pharmaceuticals, Inc. - Discontinued/Dormant Projects

Contents:

List of Tables
List of Figures
Achillion Pharmaceuticals, Inc. Snapshot
Achillion Pharmaceuticals, Inc. Overview

Key Information

Key Facts

Achillion Pharmaceuticals, Inc. – Research and Development Overview

Key Therapeutic Areas

Achillion Pharmaceuticals, Inc. – Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products – Combination Treatment Modalities

Achillion Pharmaceuticals, Inc. – Pipeline Products Glance

Achillion Pharmaceuticals, Inc. Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Achillion Pharmaceuticals, Inc.–Early Stage Pipeline Products

Pre-Clinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Achillion Pharmaceuticals, Inc. – Drug Profiles

ACH-1095

Product Description

Mechanism of Action

R&D Progress

ACH-1625

Product Description

Mechanism of Action

R&D Progress

ACH-1625 + Pegylated Interferon Alpha-2a + Ribavirin

Product Description

Mechanism of Action

R&D Progress

ACH-2684

Product Description

Mechanism of Action

R&D Progress

ACH-2881

Product Description

Mechanism of Action

R&D Progress

ACH-2928

Product Description

Mechanism of Action

R&D Progress

ACH-3080

Product Description

Mechanism of Action

R&D Progress

ACH-3102

Product Description

Mechanism of Action

R&D Progress

ACH-3107

Product Description

Mechanism of Action

R&D Progress

ACH-702

Product Description

Mechanism of Action

R&D Progress

Antibacterial Program

Elvucitabine

Product Description

Mechanism of Action
Achillion Pharmaceuticals, Inc. – Company Statement
Achillion Pharmaceuticals, Inc. – Locations And Subsidiaries

Recent Developments
Sep 30, 2010: Achillion Announces Dosing Of First Patient In Phase II Trial Of ACH-1625 For The Treatment Of Hepatitis C
Sep 30, 2010: Achillion Doses First Patient In Phase II Trial Of ACH-1625 For Treatment Of Hepatitis C
Sep 30, 2002: Achillion Pharmaceuticals Presents At ICAAC In Vitro Data Showing Anti-HIV Activity Of A New Class Of Compounds Against A Novel HIV Target
Mar 30, 2011: Achillion Announces Positive RVR Results With ACH-1625 To Treat Chronic Hepatitis C
Jun 29, 2009: Achillion Announces First-In-Human Dosing Of ACH-1625 For Treatment Of Hepatitis C
Sep 28, 2009: Achillion Completes Phase Ia Trial of ACH-1625; Begins Dosing in Phase Ib Segment With HCV-Infected Patients
Jan 28, 2010: Achillion Announces Nomination Of ACH-2684 As Lead Clinical Candidate in Resistance-Focused HCV Program
Oct 27, 2008: Achillion Presents Data From Antibacterial And HIV Programs At The 2008 ICAAC/IDSA Joint Meeting
May 25, 2011: Achillion Initiates Phase I Trial Of ACH-2684 For Treatment Of Hepatitis C
Jul 22, 2010: Achillion Announces Nomination Of NSSA Inhibitor As Lead Clinical Candidate For Treatment Of HCV
Jun 22, 2011: Achillion Initiates 12-Week Dosing In Phase II Trial Of ACH-1625 For Treatment Of Chronic Hepatitis C
Mar 18, 2010: Achillion Announces Award Of NIH Grant To Study Unique Antibacterial Compound Series
Mar 17, 2010: Achillion To Present ACH-1625 Protease Inhibitor Abstracts At International Liver Congress
Feb 17, 2010: Achillion Announces Additional Positive Phase II Trial Results Of Elvucitabine For Treatment Of HIV
Mar 16, 2011: Achillion Receives US Patent For ACH-1625 And Related Protease Inhibitors
Dec 15, 2009: Achillion Announces Positive Preliminary Phase Ib Proof of Concept Data With ACH-1625 to Treat Hepatitis C
Apr 15, 2010: Achillion Presents Data From Phase I Clinical Trial Of ACH-1625 In Hepatitis C
Apr 15, 2010: Achillion Presents Data From Studies Of ACH-1625 in Hepatitis C at the EASL International Liver Congress
Jul 11, 2011: Achillion Initiates Phase I Trial Of ACH-2928 For Treatment Of Hepatitis C
May 11, 2010: Achillion Announces Positive Once-Daily Dosing Results With ACH-1625 To Treat Hepatitis C
May 11, 2010: Achillion Announces Positive Once-Daily Dosing Results With ACH-1625 To Treat Hepatitis C
Jan 11, 2010: Achillion Announces Additional Phase Ib Results Of ACH-1625 For The Treatment Of Hepatitis C
Dec 06, 2010: Achillion Announces To Present Data From Studies Of ACH-1625 In Hepatitis C At Asian Pacific Liver Conference
Dec 06, 2010: Achillion To Present Data From Studies Of ACH-1625 In Hepatitis C At Asian Pacific Liver Conference
Jun 04, 2008: Achillion Nominates ACH-1625 As Lead Candidate In Proprietary Program Targeting HCV Protease
Financial Deals Landscape
Achillion Pharmaceuticals, Inc., Deals Summary
Achillion Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Achillion Pharmaceuticals Raises $35 Million In Series C2 Financing
Achillion Pharmaceuticals Secures $10.4 Million In Series D Financing

Licensing Agreements
Achillion Pharmaceuticals Enters Into Licensing Agreement With GCA Therapeutics
Achillion Pharmaceuticals Enters Into Licensing Agreement With FOB Synthesis
Achillion Pharmaceuticals Enters Into Licensing Agreement with Gilead Sciences

Equity Offering
Achillion Pharmaceuticals Completes An Underwritten Public Offering Of $65.1 Million
Achillion Pharmaceuticals Completes Private Placement For $50 Million
Achillion Pharmaceuticals Completes Public Offering Of $25 Million
Achillion Pharmaceuticals Announces Private Placement Of $15 Million
Achillion Pharmaceuticals Completes Private Placement Of $31 Million
Achillion Pharmaceuticals Completes Initial Public Offering Of $59.5 Million

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Achillion Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Achillion Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Achillion Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Achillion Pharmaceuticals, Inc. - Phase II, H2 2011
Achillion Pharmaceuticals, Inc. - Phase I, H2 2011
Achillion Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Achillion Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Achillion Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Achillion Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
Achillion Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Achillion Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
Achillion Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2010
Achillion Pharmaceuticals, Inc., Deals Summary
Achillion Pharmaceuticals Raises $35 Million In Series C2 Financing
Achillion Pharmaceuticals Secures $10.4 Million In Series D Financing
Achillion Pharmaceuticals Enters Into Licensing Agreement With GCA Therapeutics
Achillion Pharmaceuticals Enters Into Licensing Agreement With FOB Synthesis
Achillion Pharmaceuticals Enters Into Licensing Agreement with Gilead Sciences
Achillion Pharmaceuticals Completes An Underwritten Public Offering Of $65.1 Million
Achillion Pharmaceuticals Completes Private Placement For $50 Million
Achillion Pharmaceuticals Completes Public Offering Of $25 Million
Achillion Pharmaceuticals Announces Private Placement Of $15 Million
Achillion Pharmaceuticals Completes Private Placement Of $31 Million
Achillion Pharmaceuticals Completes Initial Public Offering Of $59.5 Million

List of Figures
Achillion Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Achillion Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Achillion Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Achillion Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011
Achillion Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Achillion Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1964476/

Order by Fax - using the form below

Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Achillion Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011
Web Address: http://www.researchandmarkets.com/reports/1964476/
Office Code: SCD2Y3NA

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
Mr ☐  Mrs ☐  Dr ☐  Miss ☐  Ms ☐  Prof ☐
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World